维普期刊资源整合服务平台（V6.5）

291篇 您的检索式：作者名="STADLER WM"

选中清除导出查看参考文献查看引证文献引用追踪共15页首页上一页第1页下一页末页 /15 跳转

	题名	作者	年代	出处	被引量
1	Sorafenib in advanced clear-cell renal -cell carcinoma 显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl JMed2007，356，2：	1
2	Sorafenib in advanced clear-cell renal-cell carcinoma显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl J Med2007，356，：	1
3	Sorafenib in advanced clearcell renal cell carcinoma显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl J Med2007，356，2：	1
4	Phase Ⅱ placebocontrolled random ized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma显示文摘	RatainMJ Eisen T Stadler WM	2006	J Clin Oncol2006，24，：	1
5	Metastasis suppressor: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site 显示文摘	Kauffman EC Robinson VL Stadler WM	2003	J Urol2003，169，3：	1
6	Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small - cell lung cancer显示文摘	Karrison TG Maitland ML Stadler WM	2007	1 Natl CancerInst2007，99，19：	1
7	Sorafenib in advanced clear-cell renal-cell carcinoma显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl J Med2007，356，2：	1
8	Sorafenib fortreatment of renal cell carcinoma: Final efficacy and safety results of the phase m treatment approaches in renal cancer global evaluation triaI显示文摘	Escudier B Eisen T Stadler WM	2009	) Clin Oneol2009，27，20：	1
9	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial显示文摘	Escudier B Eisen T Stadler WM	2009	J Clin Oncol2009，27，20：	1
10	Urinary nuclear matrix protein as a marker for transitional cell car- cinoma of the urinary tract 显示文摘	Carpinito GA Stadler WM Briggman JV	1996	J Urol1996，156，4：	1
11	Sorafenib in ad- vanced clear-cell renal-cell carcinoma 显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl J Med2007，356，2：	1
12	Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma 显示文摘	Ratain M J Eisen T Stadler WM	2006	J Clin Oncol2006，24，16：	1
13	Urirary nuclear matrix protein as a maker for transitional cell carcinoma of the urinary tract显示文摘	Carpinito GA Stadler WM Brigsman JV	1996	J Urol1996，156，4：	1
14	Final findings from a phase Ⅱ, placebo-controlled, randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43 - 9006) in patients with advanced renal cell carcinoma (RCC)(abstract) 显示文摘	Ratain MJ Eisen T Stadler WM	2005	J Clin Oncol2005，23，16：	1
15	Phase Ⅱ placebo-controlled randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)显示文摘	Ratain MJ Eisen T Stadler WM	2006	Clin Oncol2006，24，16：	1
16	A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases 显示文摘	Lara PJ Stadler WM Longmate J	2006	Clin Cancer Res2006，12，：	1
17	Phase Ⅱ placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma 显示文摘	Ratain M J Eisen T Stadler WM	2006	J Clin Oncol2006，24，16：	1
18	Sorafenib in advanced clear-cell renal-cell carcinoma 显示文摘	Escudier B Eisen T Stadler WM	2007	N Engl J Med2007，356，2：	1
19	Molecular events in the initiation and progression of bladder cancer显示文摘	Stadler WM	1993	Int J Oncol1993，3，：	1
20	Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcino- ma显示文摘	Atkins MB Hidalgo M Stadler WM	2004	J Clin Oncol2004，22，5：	1

返回顶部每页显示：

共15页首页上一页第1页下一页末页 /15 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示